APA (7th ed.) Citation

J, Q., C, L., Y, H., Y, J., X, L., X, H., . . . Y, W. (2026). Value of [18F]AlF-NOTA-FAPI PET/CT in guiding radiotherapy planning for stage I-IIIC lung cancer: A comparison with contrast-enhanced CT and [18F]FDG PET/CT. European journal of nuclear medicine and molecular imaging, 53(6), 3760. https://doi.org/10.1007/s00259-025-07753-7

Chicago Style (17th ed.) Citation

J, Qin, et al. "Value of [18F]AlF-NOTA-FAPI PET/CT in Guiding Radiotherapy Planning for Stage I-IIIC Lung Cancer: A Comparison with Contrast-enhanced CT and [18F]FDG PET/CT." European Journal of Nuclear Medicine and Molecular Imaging 53, no. 6 (2026): 3760. https://doi.org/10.1007/s00259-025-07753-7.

MLA (9th ed.) Citation

J, Qin, et al. "Value of [18F]AlF-NOTA-FAPI PET/CT in Guiding Radiotherapy Planning for Stage I-IIIC Lung Cancer: A Comparison with Contrast-enhanced CT and [18F]FDG PET/CT." European Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 6, 2026, p. 3760, https://doi.org/10.1007/s00259-025-07753-7.